Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma

被引：2

作者：

Miller, Sally D. ^{[1
]}

Lozano-Ortega, Greta ^{[1
]}

Mutebi, Alex ^{[2
]}

Briggs, Owanate ^{[2
]}

Sail, Kavita ^{[3
]}

Elliott, Brian ^{[2
]}

Kalsekar, Anupama ^{[2
]}

机构：

[1] Broadstreet HEOR, 201-343 Railway St, Vancouver, BC V6A 1A4, Canada

[2] Genmab, 777 Scudders Mill Rd, Plainsboro, NJ 08536 USA

[3] AbbVie, 1 N Waukegan Rd, Chicago, IL 60064 USA

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2023年 / 12卷 / 01期

关键词：

clinical trials; comparative effectiveness research; diffuse large B-cell lymphoma; nonrandomized trials; oncology; randomized controlled trials; refractory; relapsed; systematic review; NON-HODGKIN-LYMPHOMA; EFFECTIVE SALVAGE REGIMEN; ELDERLY-PATIENTS; SINGLE-ARM; OPEN-LABEL; PHASE-II; CHOP CHEMOTHERAPY; RESPONSE CRITERIA; PLUS RITUXIMAB; MULTICENTER;

D O I：

10.2217/cer-2022-0146

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: To evaluate trials of systemic therapies in transplant-ineligible or -experienced, relapsed/refractory diffuse large-B cell lymphoma and the impact of patient characteristics on overall response rate (ORR). Patients & methods: Systematically reviewed multiple databases through 22 July 2021. Analyzed variations in patient characteristics and their relationship with ORR across trials. Results: Among 17 included trials, key patient characteristics varied substantially: primary refractory (0-69%), refractory to last line of therapy (LOT) (12-100%), >= 2 prior LOTs (14-100%), >= 3 prior LOTs (0-64%), IPI >= 3 (23-73%), tumor stage III/IV (50-90%) and median age (56-74 years). ORRs varied substantially (25-83%), correlating with these characteristics. Conclusion: Differences in patient characteristics significantly contribute to the variability in ORR across these trials and should be considered when contextualizing efficacy data.

引用

页数：14

共 38 条

[1] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].

Abramson, Jeremy S. ;

Palomba, M. Lia ;

Gordon, Leo I. ;

Lunning, Matthew A. ;

Wang, Michael ;

Arnason, Jon ;

Mehta, Amitkumar ;

Purev, Enkhtsetseg ;

Maloney, David G. ;

Andreadis, Charalambos ;

Sehgal, Alison ;

Solomon, Scott R. ;

Ghosh, Nilanjan ;

Albertson, Tina M. ;

Garcia, Jacob ;

Kostic, Ana ;

Mallaney, Mary ;

Ogasawara, Ken ;

Newhall, Kathryn ;

Kim, Yeonhee ;

Li, Daniel ;

Siddiqi, Tanya .

LANCET, 2020, 396 (10254) :839-852

[2]

[Anonymous], 2022, CANC STAT FACTS COMM

[3]

[Anonymous], 2022, B CELL LYMPH

[4] Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial [J].

Bannerji, Rajat ;

Arnason, Jon E. ;

Advani, Ranjana H. ;

Brown, Jennifer R. ;

Allan, John N. ;

Ansell, Stephen M. ;

Barnes, Jeffrey A. ;

O'Brien, Susan M. ;

Chavez, Julio C. ;

Duell, Johannes ;

Rosenwald, Andreas ;

Crombie, Jennifer L. ;

Ufkin, Melanie ;

Li, Jingjin ;

Zhu, Min ;

Ambati, Srikanth R. ;

Chaudhry, Aafia ;

Lowy, Israel ;

Topp, Max S. .

LANCET HAEMATOLOGY, 2022, 9 (05) :E327-E339

[5] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial [J].

Caimi, Paolo F. ;

Ai, Weiyun ;

Alderuccio, Juan Pablo ;

Ardeshna, Kirit M. ;

Hamadani, Mehdi ;

Hess, Brian ;

Kahl, Brad S. ;

Radford, John ;

Solh, Melhem ;

Stathis, Anastasios ;

Zinzani, Pier Luigi ;

Havenith, Karin ;

Feingold, Jay ;

He, Shui ;

Qin, Yajuan ;

Ungar, David ;

Zhang, Xiaoyan ;

Carlo-Stella, Carmelo .

LANCET ONCOLOGY, 2021, 22 (06) :790-800

[6] Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias [J].

Cheson, BD ;

Vena, DA ;

Barrett, J ;

Freidlin, B .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2454-2460

[7] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[8] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].

Cheson, Bruce D. ;

Fisher, Richard I. ;

Barrington, Sally F. ;

Cavalli, Franco ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Lister, T. Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+

[9] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[10] Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte [J].

Coiffier, Bertrand ;

Thieblemont, Catherine ;

Van Den Neste, Eric ;

Lepeu, Gerard ;

Plantier, Isabelle ;

Castaigne, Sylvie ;

Lefort, Sophie ;

Marit, Gerald ;

Macro, Margaret ;

Sebban, Catherine ;

Belhadj, Karim ;

Bordessoule, Dominique ;

Ferme, Christophe ;

Tilly, Herve .

BLOOD, 2010, 116 (12) :2040-2045

← 1 2 3 4 →